Sudarshan Pharma Industries (543828) Investor presentation summary

Acquisition overview

• Proposed acquisition of a USFDA-approved manufacturing unit specializing in APIs and intermediates.

• Facility is 40 km from Visakhapatnam Airport, spread over 14 acres, and does not manufacture steroids, penicillin, beta-lactam antibiotics, hormones, or cytotoxic products.

• Site benefits from robust infrastructure, including water supply, effluent treatment, and hazardous waste management.

Facility and operations

• Four manufacturing blocks and a solvent recovery plant with a total capacity of 584 KL; all blocks are multi-product facilities.

• 24/7 operations with 200 employees across production, quality, R&D, engineering, and support functions.

• Comprehensive material management with segregated storage for raw materials, packaging, finished goods, and hazardous materials.

• Utilities include 33 KVA power, backup generators, advanced cooling, steam, compressed air, and water systems.

Quality and compliance

• Holds GMP, ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certifications.

• Approved by USFDA (ANDA-217608), WHO Geneva, and ANVISA.

• Quality policy emphasizes international standards, customer satisfaction, and cost-effective operations.

• Quality control complies with 21 CFR Part 11, including computer system validation, audit trails, and disaster recovery.

• Stability studies conducted per ICH guidelines, with chambers for accelerated and long-term conditions.